FIGURE 1.

lncRNA XLOC013218 (XLOC) upregulation correlates to temozolomide (TMZ) resistance and poor prognosis in glioma. A, Experiment design to investigate the role of lncRNAs in glioblastoma multiforme (GBM) TMZ resistance. B, Agarose gel electrophoresis showed the PCR products amplified from 5’ RACE and 3’ RACE of XLOC. C, XLOC expression level in TMZ‐resistant (TR) cells and their parent cells. D, Expression levels of XLOC in normal human astrocyte (NHA) cells and glioma cells (SHG44, U87, U118, U251, and A172). E, XLOC expression in high‐grade gliomas (WHO III‐IV) and low‐grade gliomas (WHO II). F, XLOC expression in primary and recurrent GBM tissues. G, 73 GBM patients were classified into two groups (XLOC‐low, n = 36; XLOC‐high, n = 37) based on median value of XLOC; Kaplan‐Meier overall survival analysis of GBM patients based on XLOC expression. Data are presented as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001